S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
OTCMKTS:CYDY

CytoDyn Stock Forecast, Price & News

$4.81
-0.20 (-3.90 %)
(As of 01/25/2021 05:19 PM ET)
Add
Compare
Today's Range
$4.75
Now: $4.81▼
$5.00
50-Day Range
$2.33
MA: $4.64▼
$6.00
52-Week Range
$0.79
Now: $4.81▼
$10.01
Volume2.46 million shs
Average Volume3.29 million shs
Market Capitalization$2.88 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.64
CytoDyn Inc., a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
CytoDyn logo

MarketRank™

Overall MarketRank™

0.72 out of 5 stars

Medical Sector

1178th out of 1,922 stocks

Pharmaceutical Preparations Industry

546th out of 771 stocks

Analyst Opinion: 1.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CYDY
Previous SymbolNASDAQ:CYDY
CUSIP23283M101
CIK1175680
Webwww.cytodyn.com
Phone360-980-8524
Employees19
Year FoundedN/A

Debt

Debt-to-Equity Ratio5.01
Current Ratio1.13
Quick Ratio0.28

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.01) per share
Price / Book-481.00

Profitability

EPS (Most Recent Fiscal Year)($0.21)
Net Income$-124,400,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-153.30%

Miscellaneous

Outstanding Shares598,356,000
Market Cap$2.88 billion
Next Earnings Date4/8/2021 (Estimated)
OptionableNot Optionable
$4.81
-0.20 (-3.90 %)
(As of 01/25/2021 05:19 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CYDY News and Ratings via Email

Sign-up to receive the latest news and ratings for CYDY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CytoDyn (OTCMKTS:CYDY) Frequently Asked Questions

How has CytoDyn's stock been impacted by Coronavirus?

CytoDyn's stock was trading at $1.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CYDY shares have increased by 385.9% and is now trading at $5.0050.
View which stocks have been most impacted by COVID-19.

Is CytoDyn a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytoDyn in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CytoDyn stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CYDY, but not buy additional shares or sell existing shares.
View analyst ratings for CytoDyn or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than CytoDyn?

Wall Street analysts have given CytoDyn a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CytoDyn wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is CytoDyn's next earnings date?

CytoDyn is scheduled to release its next quarterly earnings announcement on Thursday, April 8th 2021.
View our earnings forecast for CytoDyn.

How were CytoDyn's earnings last quarter?

CytoDyn Inc. (OTCMKTS:CYDY) posted its earnings results on Tuesday, October, 9th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.01.
View CytoDyn's earnings history.

What price target have analysts set for CYDY?

1 brokerages have issued 1-year price targets for CytoDyn's shares. Their forecasts range from $4.00 to $4.00. On average, they expect CytoDyn's share price to reach $4.00 in the next twelve months. This suggests that the stock has a possible downside of 20.1%.
View analysts' price targets for CytoDyn or view Wall Street analyst' top-rated stocks.

Who are some of CytoDyn's key competitors?

Some companies that are related to CytoDyn include Dr. Reddy's Laboratories (RDY), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), ACADIA Pharmaceuticals (ACAD), Sarepta Therapeutics (SRPT), United Therapeutics (UTHR), Galapagos (GLPG) and Allakos (ALLK).
View all of CYDY's competitors.

What other stocks do shareholders of CytoDyn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytoDyn investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), NVIDIA (NVDA), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Vaxart (VXRT), Nokia (NOK), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Moderna (MRNA).

Who are CytoDyn's key executives?

CytoDyn's management team includes the following people:
  • Dr. Scott A. Kelly, Chairman, Chief Medical Officer & Head of Bus. Devel. (Age 50, Pay $208.22k)
  • Dr. Nader Z. Pourhassan, CEO, Pres & Director (Age 57, Pay $1.53M)
  • Mr. Michael D. Mulholland CPA, CPA, Chief Financial Officer (Age 68, Pay $445.43k)
  • Dr. Nitya G. Ray, CTO and Head of Process Sciences, Manufacturing & Supply Chain (Age 67, Pay $563k)
  • Dr. Mahboob U. Rahman FACR, M.D., Ph.D., Chief Scientific Officer
  • Ms. Arian Colachis, VP, Gen. Counsel & Sec. (Age 58)
  • Dr. Brendan P. Rae, Sr. VP of Bus. Devel.
  • Mr. George Bitar, Head of Quality & Exec. Director
  • Mr. Brian Brothen, Sr. VP of Global Oncology
  • Dr. Denis R. Burger, Scientific Consultant (Age 76)

What is CytoDyn's stock symbol?

CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY."

How do I buy shares of CytoDyn?

Shares of CYDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CytoDyn's stock price today?

One share of CYDY stock can currently be purchased for approximately $5.01.

How big of a company is CytoDyn?

CytoDyn has a market capitalization of $2.99 billion. The biotechnology company earns $-124,400,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. CytoDyn employs 19 workers across the globe.

What is CytoDyn's official website?

The official website for CytoDyn is www.cytodyn.com.

How can I contact CytoDyn?

CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The biotechnology company can be reached via phone at 360-980-8524 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.